Eugenia Carrillo
Overview
Explore the profile of Eugenia Carrillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torres A, Younis B, Tesema S, Solana J, Moreno J, Martin-Galiano A, et al.
PLoS Negl Trop Dis
. 2025 Mar;
19(3):e0012924.
PMID: 40067811
Background: Post-kala-azar dermal leishmaniasis (PKDL) appears as a rash in some individuals who have recovered from visceral leishmaniasis caused by Leishmania donovani. Today, basic knowledge of this neglected disease and...
2.
Torres A, Younis B, Alamin M, Tesema S, Bernardo L, Solana J, et al.
J Epidemiol Glob Health
. 2024 Jul;
14(3):1167-1179.
PMID: 39007942
Background: The host cellular immune response associated with two treatments for post-kala-azar dermal leishmaniasis (PKDL) - paromomycin plus miltefosine (Arm 1), and liposomal amphotericin B plus miltefosine (Arm 2) -...
3.
Torres A, Bernardo L, Sanchez C, Morato E, Solana J, Carrillo E
Biol Proced Online
. 2024 Jun;
26(1):18.
PMID: 38898416
Background: The lack of standardized protocols for isolating extracellular vesicles (EVs), especially from biobank-stored blood plasma, translates to limitations for the study of new biomarkers. This study examines whether a...
4.
van Dijk N, Hagos D, Huggins D, Carrillo E, Ajala S, Chicharro C, et al.
PLoS Negl Trop Dis
. 2024 May;
18(5):e0011637.
PMID: 38713648
Background: Diagnosis of visceral leishmaniasis (VL) in resource-limited endemic regions is currently based on serological testing with rK39 immunochromatographic tests (ICTs). However, rK39 ICT frequently has suboptimal diagnostic accuracy. Furthermore,...
5.
Bernardo L, Ibarra-Meneses A, Douanne N, Corbeil A, Solana J, Beaudry F, et al.
PLoS Negl Trop Dis
. 2024 Feb;
18(2):e0012015.
PMID: 38422164
Background: Visceral leishmaniasis (VL) resolution depends on a wide range of factors, including the instauration of an effective treatment coupled to a functional host immune system. Patients with a depressed...
6.
Bernardo L, Solana J, Sanchez C, Torres A, Reyes-Cruz E, Carrillo E, et al.
Front Immunol
. 2023 Dec;
14:1285943.
PMID: 38106411
Background: Immunosuppression is a major risk factor for the development of visceral leishmaniasis (VL). The number of patients receiving immunosuppressant drugs such as TNF antagonist (anti-TNF) and methotrexate (MTX) is...
7.
Deni A, De Pascali A, Ortalli M, Balducelli E, Provenzano M, Ferrara F, et al.
Int J Infect Dis
. 2023 Nov;
138:81-83.
PMID: 37995832
Objectives: In immunocompromised patients, asymptomatic Leishmania infection can reactivate, and evolve to severe disease. To date, no test is considered the gold standard for the identification of asymptomatic Leishmania infection....
8.
Nastase A, Barrett M, Cardenas W, Cordeiro F, Zambrano M, Andrade J, et al.
PLoS Negl Trop Dis
. 2023 Jul;
17(7):e0011133.
PMID: 37486920
Acute febrile illnesses are still a major cause of mortality and morbidity globally, particularly in low to middle income countries. The aim of this study was to determine any possible...
9.
De Pascali A, Todeschini R, Baiocchi S, Ortalli M, Attard L, Ibarra-Meneses A, et al.
PLoS Negl Trop Dis
. 2022 Aug;
16(8):e0010676.
PMID: 35969605
Background: Most people infected with Leishmania remain asymptomatic, which is a common element that may promote the resurgence of clinically evident leishmaniasis in individuals with impaired cell-mediated immune responses. Unfortunately,...
10.
Carrasco-Anton N, Ibarra-Meneses A, Carrillo E, Fernandez-Ruiz M, Hernandez-Jimenez P, Aguado J, et al.
J Infect
. 2022 Feb;
84(4):573-578.
PMID: 35101535
Objective: Sensitive and less laborious assays are needed to detect asymptomatic Leishmania among solid organ transplant (SOT) recipients. Using SLA-stimulated plasma from SOT recipients living where an outbreak of Leishmania...